Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts
Shares of Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) have earned an average recommendation of “Buy” from the six ratings firms that are currently covering the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $24.00.
A number of research analysts have recently weighed in on the company. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Credit Suisse Group AG reiterated a “buy” rating and set a $25.00 price target on shares of Corvus Pharmaceuticals in a report on Tuesday, September 27th. Finally, Cantor Fitzgerald set a $23.00 price target on Corvus Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, August 6th.
A number of hedge funds and other institutional investors have recently modified their holdings of CRVS. State Street Corp purchased a new position in shares of Corvus Pharmaceuticals during the second quarter worth approximately $407,000. FMR LLC increased its position in shares of Corvus Pharmaceuticals by 5.3% in the second quarter. FMR LLC now owns 2,311,297 shares of the company’s stock worth $32,959,000 after buying an additional 116,500 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Corvus Pharmaceuticals by 1,081.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 35,734 shares of the company’s stock worth $510,000 after buying an additional 32,710 shares during the period. BlackRock Fund Advisors purchased a new position in shares of Corvus Pharmaceuticals during the second quarter worth approximately $1,248,000. Finally, BlackRock Investment Management LLC increased its position in shares of Corvus Pharmaceuticals by 143.0% in the second quarter. BlackRock Investment Management LLC now owns 12,394 shares of the company’s stock worth $177,000 after buying an additional 7,294 shares during the period. Hedge funds and other institutional investors own 82.91% of the company’s stock.
Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) opened at 16.39 on Friday. The company’s 50 day moving average price is $14.94 and its 200 day moving average price is $14.01. The stock’s market capitalization is $342.70 million. Corvus Pharmaceuticals has a one year low of $9.63 and a one year high of $17.77.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.
Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.